Showing 1 - 10 of 15
In economic evaluation, mathematical models have a central role as a way of integrating all the relevant information about a disease and health interventions, in order to estimate costs and consequences over an extended time horizon. Models are based on scientific knowledge of disease (which is...
Persistent link: https://www.econbiz.de/10010614295
<Emphasis Type="Bold">Background: The importance of assessing the accuracy of health economic decision models is widely recognized. Many applied decision models (implicitly) assume that the process of identifying relevant values for a model’s input parameters is sufficient to prove the model’s accuracy. The...</emphasis>
Persistent link: https://www.econbiz.de/10011001704
Background: The importance of assessing the accuracy of health economic decision models is widely recognized. Many applied decision models (implicitly) assume that the process of identifying relevant values for a model's input parameters is sufficient to prove the model's accuracy. The selection...
Persistent link: https://www.econbiz.de/10010614381
Persistent link: https://www.econbiz.de/10010848949
Modelling in economic evaluation is an unavoidable fact of life. Cohort-based state transition models are most common, though discrete event simulation (DES) is increasingly being used to implement more complex model structures. The benefits of DES relate to the greater flexibility around the...
Persistent link: https://www.econbiz.de/10010849015
Depression is the most common mental health disorder and is recognized as a chronic disease characterized by multiple acute episodes/relapses. Although modelling techniques play an increasingly important role in the economic evaluation of depression interventions, comparatively little attention...
Persistent link: https://www.econbiz.de/10010548284
Persistent link: https://www.econbiz.de/10010614409
We reviewed the clinical measures used in rheumatoid arthritis (RA) economic evaluations with respect to their relevance and sensitivity to changes in survival, health-related quality of life (HR-QOL) and costs. We compared the measures from the economic perspective and discussed the validity of...
Persistent link: https://www.econbiz.de/10005449252
Background: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years' adjuvant tamoxifen therapy. The objective of this evaluation...
Persistent link: https://www.econbiz.de/10005404967
Background: There remains uncertainty around the appropriate choice of adjuvant therapies to offer postmenopausal women with node-positive early breast cancer. Objective and study design: To present the results derived from a discrete event simulation (DES) model that compared tamoxifen plus...
Persistent link: https://www.econbiz.de/10005590280